Lek enhances its competitiveness with a new plant in Lendava
Lek, a Sandoz company, opened a new plant at its Lendava site for the final phases of isolation of potassium clavulanate, which is the key ingredient of Amoksiklav, one of Lek's leading products that ranks among leading products also in Sandoz. Regular production of potassium clavulanate began in 1992 and today it is the most important product of this site. With the new plant, Lek is additionally solidifying the significance of the Lendava site, which is an important production center for selected active ingredients for global markets within the framework of Sandoz, one of leading global generic pharmaceutical companies. With events upon the opening of the new plant, Lek also marked 20 years of successful production of pharmaceutical active ingredients in Lendava.
The plant, which will employ 12 people, is in compliance with the strictest requirements for final phases of production of pharmaceutical active ingredients that are stipulated by the Slovene legislation and expected by customers from the most demanding pharmaceutical markets. The latest standards in the field of fire safety and explosion-proof operation, as well as environmental protection, are also taken into account. Compared to the old plant, the new one also has three times the production capacity.
The plant for final phases of potassium clavulanate isolation in Lendava was officially opened by Lek's CEO Janja Bratos and the Mayor of Lendava, Anton Balazek M.Sc., together with the director of the Lek plant in Lendava, Dr. Ales Rokavec.
Sandoz Canada announced that it will invest $80 million in its Boucherville facilities as demand for its generic sterile injectable pharmaceuticals continues to grow in Canada and around the world. In addition to more than 100 new positions created in 2006, 100 additional jobs will be creat ... more
PLIVA d.d. announced that an agreement has been signed with Novartis' generics division, Sandoz, for the purchase of its Spanish subsidiary Uso Racional S.L (UR) for a total cash consideration of EUR 21.5m. With expected sales of about EUR 12m in 2006, UR represents a well known and establi ... more